Saluda Medical在现有和新投资者的参与下,获得了由Redmile Group牵头的1亿美元融资。这些资金将用于推进其Evoke神经调节系统的商业化,这是该公司专有平台的首次商业应用。Evoke通过脊髓刺激治疗慢性疼痛,感知和测量神经反应以自动调整治疗。这通过维持目标水平的神经激活来确保一致,有效的结果。该系统还提供生理SC来治疗各...
Image Credit: Saluda Medical In February 2022 FDA approved Saluds Medical’s Evoke® Spinal Cord Stimulation (SCS) System (Evoke System), which is an implanted, rechargeable spinal cord stimulation system intended to treat chronic, intractable pain in the trunk or limbs. ...
Saluda Medical拿到1亿美元,助力Evoke脊髓刺激器进军市场! 近日,Saluda完成了由Redmile Group领投、Wellington Management等多家机构跟投的1亿美元融资,资金将用于加速Evoke刺激器的商业化进程,巩固其在神经调节疗法领域的领先地位。自2015年以来,Saluda已完成六轮融资,总额达3.995亿美元,凭借产品创新和巨大的市场需求,推动...
In addition, it has designed Evoke to be the first closed-loop SCS system that measures the spinal cord’s response to stimulation and adjusts on every pulse to maintain activation within the patient’s therapeutic window. Saluda Medical CEO John Parker said: “This equity financing in combinati...
About Saluda Medical Saluda Medical is a global company transforming patients’ lives with disruptive neural sensing technologies designed to revolutionize the field of neuromodulation. The company’s first product, the Evoke®System, is the only SmartLoop™ therapy with physiologic ECAP-controlled clo...
Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. Investor Contacts: Brian Johnston orSam Bentzinger brian@gilmartinir.com sam@gilmartinir.com SOURCE Saluda Medical
technology in the field of SCS is still in its infancy. Energy is still being delivered into the spinal cord without measuring the actual physiologic response to stimulation. Using objective physiologic response data, the Evoke system has been developed to realize substantial improvements in pain, fu...
Saluda Medical作为全球首个获得FDA批准的闭环脊髓刺激器技术公司,不久前成功完成1亿美元的融资。这笔巨额融资将推动他们的核心产品Evoke的商业化进程,进一步巩固Saluda在神经调节治疗领域的领先地位。如果你在寻找慢性疼痛的解救之法,这里或许是个新希望。 Evoke系统的问世并非偶然。对于许多因慢性疼痛而饱受折磨的患者来...
近日,位于澳大利亚的医疗器械公司Saluda Medical 宣布,其治疗慢性疼痛的Evoke®脊髓刺激(SCS)系统获得美国食品药品监督管理局(FDA)的批准,将于2023年全面上市,这是全球第一个通过 ECAP(诱发复合动作电位)控制的闭环脊髓刺激系统。 Saluda Medical是一家开发神经调节医疗器械的公司,成立于2013年,前身是2009年John Parker...
近日,位于澳大利亚的医疗器械公司Saluda Medical 宣布,其治疗慢性疼痛的Evoke ® 脊髓刺激(SCS)系统获得美国食品药品监督管理局(FDA)的批准,将于2023年全面上市,这是全球第一个通过 ECAP(诱发复合动作电位)控制的闭环脊髓刺激系统。 Saluda Medical是一家开发神经调节医疗器械的公司,成立于2013年,前身是2009年John Par...